Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies

Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies

The phosphoinositide 3-kinase (PI3K) pathway remains a potent drug target in hematological malignancies despite the challenges that have affected clinical drug development, particularly unpredictable toxicity, and inherent/acquired drug resistance. Herein, we tested the activity of a novel PI3Kδ se...

Full description

Saved in:
Bibliographic Details
Main Authors: Binu Kandathilparambil Sasi, Chiara Tarantelli, Stephen Martindale, Elisa Civanelli, Eleonora Cannas, Giulio Sartori, Alberto J. Arribas, Stacey M. Fernandes, Samantha J. Shupe, John-Hanson Machado, Svitlana Tyekucheva, Yue Ren, Michael Lahn, Lars van der Veen, Giusy Di Conza, Francesco Bertoni, Jennifer R. Brown
Format: Article
Language:English
Published: Ferrata Storti Foundation 2025-06-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/12114
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://haematologica.org/article/view/12114

Similar Items